Although numerous inhibitors are under development to selectively intervene the HIF-1 pathway10, including an LNA-based anti-sense oligonucleotide (EZN-2968) that inhibits HIF-1α mRNA and demonstrates limited anti-tumor effect in phase I trial11,12, targeting HIF-1α per se seems not to be effective in reversing glucose metabolic reprograming and appears toxic7. This evidence concerns the gene HIF1A and neoplasm.